Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

from Dew -

Teva’s thrice-weekly Copaxone will be reviewed under an NDA. If approved, it could cannibalize some of the market for regular Copaxone, including the generic versions; however, thrice-weekly Copaxone will require an explicit prescription and won’t be substitutable for an Rx written for regular Copaxone.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72989576

from Genisi -

The thrice-weekly Copaxone formulation (GALA study) is not low volume, rather it's a stronger dose (40mg glatiramer acetate instead of 20mg).

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72990439&txt2find=gala